Studies / Research

Clinical Trials

Biocept is dedicated to supporting its partners, collaborators, and clients with our unique CNSide™ CSF-TC and cfDNA technology platforms for rare event detection and genetic characterization. Our CLIA-licensed and CAP-accredited laboratory combines a highly trained professional staff who are experienced in assay development with innovative instrumentation for optimal test results and quality control.

Our CNSide™ platforms provide flexibility for developing assays with unique requirements for our partners. This development can be performed in our CLIA laboratory.  We focus on providing high-level, personalized service to our clients, addressing critical questions of interest to them including:

  • Assay development
  • Patient population profiling
  • Determination of patient eligibility/stratification for clinical trials
  • Measuring efficacy endpoints
  • Correlative science studies

Please contact Clinical Affairs for more information at 888.332.7729 or via email at foresee_study@biocept.com.

How Biocept is Creating the Future

We’re building partnerships that redefine the boundaries of personalized cancer medicine.

Learn More